Company Profile

Kadmon Holdings, Inc. is a biopharmaceutical company, which is engaged in discovering, developing, and delivering therapies for unmet medical needs. The Company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. It is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The Company has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.

Employees

127

Sector

Pharmaceuticals

More about the company

21-12-21	Sanofi in $1 bln deal to buy U.S.-based Amunix Pharma	RE
21-12-01	Sanofi to buy Origimm Biotechnology for acne vaccine candidate	RE
21-11-10	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Global BMI Index	CI
21-11-10	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P TMI Index	CI
21-11-10	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Biotechnology Select Industry Index	CI
21-11-09	Sanofi Closes on Kadmon Acquisition	MT
21-11-09	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Composite Index	CI
21-11-08	Sanofi completed the acquisition of Kadmon Holdings, Inc..	CI
21-11-08	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Biotechnology Index	CI
21-11-04	Kadmon Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
21-11-04	Earnings Flash (KDMN) KADMON HOLDINGS Reports Q3 Revenue $14.7M	MT
21-10-21	Kadmon : Health Care Stocks Edging Higher At Close	MT
21-10-21	Kadmon : Announces Expiration of HSR Waiting Period in Sanofi Deal	MT

21-09-14	Kadmon : Mizuho Securities Downgrades Kadmon Holdings to Neutral from Buy, Adjusts Price Target to $9.50 from $13	MT
21-09-10	Kadmon : UBS Downgrades Kadmon Holdings to Neutral From Buy, Adjusts PT to $9.50 From $9	MT
21-09-09	Kadmon : Oppenheimer Suspends Rating for Kadmon Holdings Following Sanofi Merger	MT
21-09-09	Kadmon : Jefferies Downgrades Kadmon Holdings to Hold from Buy, Adjusts Price Target to $9.50 from $10	MT
21-07-19	Kadmon : Oppenheimer Adjusts Kadmon Holdings PT to $9 From $8, Maintains Outperform Rating	MT

21-11-09	Sanofi completes acquisition of Kadmon - Form 8-K	PU
21-11-09	KADMON HOLDINGS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendme (form 8-K)	AQ
21-11-05	KADMON HOLDINGS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
21-11-04	Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results	PU
21-11-04	KADMON HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ

22-02-04	Sanofi wächst weiter - Neurodermitis-Mittel bringt Schwung
22-01-07	Sanofi : renforce dans l'Intelligence Artificielle appliquée à l'oncologie et l'immunologie
21-12-21	Weiterer Milliardendeal: Sanofi will US-Krebsspezialisten Amunix übernehmen
21-12-21	Sanofi : La valeur du jour à Paris Sanofi signe une nouvelle acquisition
21-12-21	Sanofi übernimmt US-Krebsspezialisten für gut eine Milliarde Dollar

Manager	Title	Age	Since
Gustavo J. Pesquin CEO	Chief Executive Officer	56	2021-11-08
Steven Meehan DFI	Director of Finance/CFO	62	2019-02-07
John Ryan CTO	Chief Tech/Sci/R&D Officer	82	2010-12-31

Kadmon Holdings, Inc. Stock

Stocks

KDMN

US48283N1063

Pharmaceuticals

Latest news: Kadmon Holdings, Inc.

Analysts' recommendations: Kadmon Holdings, Inc.

Press Releases: Kadmon Holdings, Inc.

News in other languages: Kadmon Holdings, Inc.

Quotes and Performance

Managers and Directors: Kadmon Holdings, Inc.

Latest insider transactions

Biopharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/9/21	Arthur Kirsch	Issuer sale	Director	376,112	0.2134%
11/9/21	David Cohen	Issuer sale	Director	346,944	0.1969%
11/9/21	Steven Meehan	Issuer sale	Chief Financial Officer	1,994,909	1.1319%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADMON HOLDINGS, INC.	+0.21%	+0.42%	-	-	1.7B
ELI LILLY AND COMPANY	+0.02%	+0.87%	+47.07%	+137.86%	1,258B
JOHNSON & JOHNSON	-0.49%	+5.81%	+49.48%	+91.26%	679B
ABBVIE INC.	-0.34%	+2.32%	+33.80%	+111.16%	518B
ROCHE HOLDING AG	-0.04%	+2.51%	+43.71%	+69.29%	390B
MERCK & CO., INC.	-1.65%	+1.45%	+69.19%	+44.76%	367B
NOVARTIS AG	+0.78%	+2.37%	+31.72%	+60.53%	307B
ASTRAZENECA PLC	-0.85%	+1.56%	+6.46%	+38.49%	293B
AMGEN INC.	-0.52%	+0.43%	+43.13%	+73.30%	252B
GILEAD SCIENCES, INC.	-0.18%	+0.85%	+42.95%	+122.46%	210B
Average	-0.24%	+1.05%	+40.84%	+83.24%	475B
Weighted average by Cap.	-0.17%	+1.18%	+43.12%	+96.05%